cathepsin 8 Inhibitors

The cathepsin 8 inhibitors represent a class of compounds designed to modulate the activity of cathepsin 8, a member of the C1 family of peptidases. Cathepsin 8 functions as a lysosomal cysteine protease with both endopeptidase and exopeptidase activities, playing a crucial role in protein turnover. Additionally, cathepsin 8 is known as amyloid precursor protein secretase, participating in the proteolytic processing of amyloid precursor protein (APP). Incomplete proteolytic processing of APP has been implicated in Alzheimer's disease, a neurodegenerative disorder. Direct inhibitors such as E-64, Leupeptin, CA-074, Odanacatib, Z-FA-FMK, and others target cathepsin 8 by inhibiting its cysteine protease activity. These compounds disrupt lysosomal protein turnover and the processing of APP, altering both endopeptidase and exopeptidase functions. For example, CA-074 specifically inhibits cathepsin 8, disrupting its cysteine protease activity and potentially impacting Alzheimer's disease-related pathogenesis by modulating APP processing.

Indirect inhibitors like FYDM-MA, NSC 687852, Wortmannin, and U0126 influence cathepsin 8 activity by targeting specific signaling pathways. FYDM-MA interferes with the mTOR pathway, NSC 687852 modulates the JNK signaling pathway, Wortmannin influences the PI3K/Akt pathway, and U0126 impacts the MAPK/ERK signaling pathway. These compounds indirectly affect cathepsin 8, altering lysosomal protein turnover and APP processing, potentially contributing to the understanding of Alzheimer's disease mechanisms. The intricate interplay of these inhibitors showcases the complex regulatory network involving cathepsin 8 and its role in cellular processes, particularly in the context of neurodegenerative diseases.